Should you sell Imperial Brands and buy AstraZeneca plc and Taylor Wimpey plc instead?

Should holders of Imperial Brands plc (LON:IMB) quit while they’re ahead and flock to Astrazeneca plc (LON:AZN) or Taylor Wimpey plc (LON:TW)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Cut your losers and run your winners” is the old investing mantra. But when does it make sense to sell your most profitable holdings? Let’s look at one FTSE 100 success story and the case for replacing it with two of its peers.

Running out of puff?

Savvy investors will have done exceedingly well from Imperial Brands (LSE:IMB) over the years. Those who invested back in 2000 will have enjoyed watching the shares rise over 1,200% since. Imperial’s shares currently trade on a fairly decent price-to-earnings (P/E) ratio of just under 16. The yield is over 4% and covered by earnings. What’s not to like?

Well, while the company may benefit from a Brexit vote due to a depreciation in sterling, there are reasons to be cautious regarding the tobacco industry’s long-term future. More than 170 countries have now introduced smoking bans in public places and recent academic research has shown that, where a ban exists, fewer people are smoking. Indeed, last month, Imperial reported falling sales in the UK. The industry as a whole also lost its case against the Government’s plain packaging policy.

True, the addictive nature of the company’s products and the growing popularity of vaping can probably deal with obstacles such as standardised packaging. Nevertheless, in my view, long-term holders of the stock should consider the benefits of leaving the party when they’re having the most fun.

Pipeline potential

A complete alternative to Imperial Brands is pharmaceutical giant AstraZeneca (LSE:AZN). Since Pfizer’s infamous approach back in 2014, things have gone relatively quiet. That May, its shares reached 4,808p. They’re now 3,964p, suggesting that investors are growing tired of the obligatory if understandable ‘jam tomorrow’ message on its pipeline and/or are concerned about the impending referendum.

Nonetheless, the company’s shares now trade on a P/E of just under 15, which indicates they could be a decent buy, despite ongoing concerns about when its next blockbusting product will arrive. The yield, at around 4.75% for the current year, will also be attractive to income investors desperate for better returns than those offered by cash.

AstraZeneca next updates the market in July. This should provide clues on the likely direction of the share price in the near term, as long as global events don’t interfere.

Shaky foundations?

Taylor Wimpey (LSE:TW), like Imperial Brands, is another example of when it can be beneficial to invest at the point of maximum pessimism. Back in November 2008, shares fell to 7.5p. Last month, they reached 210p. However, the general belief that housebuilders will suffer in the event of a Brexit has upset things somewhat and the price is now back to 188p. While a Brexit is likely to affect those with significant exposure to the London housing market (Berkeley Group, for example), it’s very unlikely Taylor Wimpey will escape unscathed. Yesterday’s prediction by surveyors that house prices are expected to fall in the short-term isn’t helping matters either.

The housebuilder currently trades on a P/E value of just under 11, according to Stockopedia with its massive 5.89% yield adequately covered by earnings.

The general media circus surrounding opinion polls over the past few weeks is unlikely to go away before the crucial vote. Nervous investors may wish to hold off completely but those confident of the UK remaining in the EU may be regard this uncertainty as a golden opportunity to build a holding in the company.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »